There were two primary goals: to assess the proportion of patients achieving MASH resolution without worsening liver fibrosis and the proportion of patients experiencing significant fibrosis reductions without MASH worsening, Newly presented results showed that both of those goals were met, with a significantly higher proportion of patients in the semaglutide group achieving either of those outcomes relative to those given a placebo
Nature 372 , 425432 (1994)
Can tirzepatide help arthritis pain
Comprehensive options like Zepbound, a dual GIP/GLP-1agonist, offer enhanced results by targeting two hormonal pathways
These benefits include reductions in cardiovascular death, non-fatal myocardial infarction, and non-fatal stroke, as shown in landmark trials such as LEADER (liraglutide), SUSTAIN-6 (semaglutide), and REWIND (dulaglutide)